clinical trial · NCT07559929
A Study of DXC006 With Immune Checkpoint Inhibitors or Platinum for Small Cell Lung Cancer.
Hangzhou DAC Biotechnology Co., Ltd.·phase2·recruiting·n = 200
Small Cell Lung CancerDXC006ToripalimabCarboplatinCisplatin
brief summary
This is a Phase Ib/II, open-label clinical study designed to evaluate the safety, tolerability, preliminary anti-tumor activity, recommended Phase 2 dose (RP2D), pharmacokinetic (PK) characteristics, and immunogenicity of DXC006 in combination with an immune checkpoint inhibitor (ICI) or platinum-based chemotherapy in patients with small cell lung cancer (SCLC).
started
Aug 19, 2026
primary completion
Jun 1, 2028
completion
Dec 30, 2030
last updated
Sep 24, 2026
official title
A Phase Ib/II Study to Evaluate the Safety and Efficacy of DXC006 for Injection Combined With Immune Checkpoint Inhibitors or Platinum-Based Agents in Patients With Small Cell Lung Cancer.
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol